About 17 percent of the faculty members at MD Anderson Cancer Center signed a petition that disagreed with the institution’s Faculty Senate in its efforts to step in and improve morale at the Houston-based institution.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
